AVRO News and Press, AVROBIO Inc. From 02/04/20

Analyst and investor event to be webcast on Monday, Feb. 10, 2020, at 7:00 p.m. ET AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company will provide clinical data...

FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato ™ platform AVROBIO (NASDAQ: AVRO) (the “Companyȁ...

2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...

Healthcare companies filing for mixed shelf offerings: More news on: Lannett Company, Inc., AVROBIO, Inc., UroGen Pharma Ltd., Healthcare stocks news, Read more ...

Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene thera...

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as an inducement award outside of...

Capital Structure Price per share: ~$21 | Market capitalization: ~$650M Cash and cash equivalents: $206M | Debt: NA Cash burn: ~$20M/quarter | Cash runway: into 2021 Commercial assets: 0 | Phase 3: 0 | Phase 2: 1 | Phase 1: 2 Introduction AVROBIO ( AVRO ) is a phase 2 biotechn...

Gene therapy is a biological product that mediates its effect by transcription and/or translation of transferred genetic material by integrating into the host genome. It is administered as nucleic acids, viruses, or genetically engineered microorganisms. In gene therapy, a normal gene is inserte...

Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...

AVROBIO (NASDAQ: AVRO ): Q3 GAAP EPS of -$0.57 beats by $0.02 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...